Follicular lymphoma trials in Germany
19 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Berlin, Cologne, Magdeburg
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - Phase 1/2Taking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Essen, Giessen, Munich, Wuerzburg
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - Phase 2/3Taking peopleA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Where
- Wuerzburg
- Age
- 18 years and over
- People
- 960 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00 - Phase 1Taking peopleA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Berlin, München, Münster
- Age
- 18 years and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - Phase 1Taking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Cologne, Essen, Frankfurt Am Main
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - Phase 3Taking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Berlin, Deggendorf, Duesseldorf, Goettingen, Hamburg, Heidelberg, Jena, Karlsruhe, Luebeck, Magdeburg, Minden, Muenster, Munich, Regensburg, Wuerzburg
- Age
- 18 years to 130 years
- People
- 1,018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - Phase 2Taking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Berlin, Chemnitz, Essen, Jena, Wuerzburg
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - Phase 3Taking peopleA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Where
- Essen, Frankfurt (Oder), Halle (Saale), Kiel, Mainz, Munich, Mutlangen, Neuss, Stuttgart
- Age
- 18 years and over
- People
- 580 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00 - Phase 3Taking peopleA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Where
- Berlin, Dresden, Frankfurt am Main, Kiel, Mainz, Mutlangen, Stuttgart, Würzburg
- Age
- 18 years and over
- People
- 822 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Göttingen, München, Ulm, Würzburg
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - No phaseTaking peopleZanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- Where
- Lübeck
- Age
- 18 years and over
- People
- 845 worldwide
- Run by
- iOMEDICO AG
See details and how to joinNCT05326308 - Phase 2Taking peopleCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Dortmund, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Halle Saale, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kiel, Luebeck, Mainz, Marburg, Minden, Muenster, Munich, Mutlangen, Offenburg, Oldenburg, Paderborn, Regensburg, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01 - No phaseTaking peopleRegistry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
- Where
- Freiburg im Breisgau
- Age
- 18 years and over
- People
- 2,950
- Run by
- iOMEDICO AG
See details and how to joinNCT06043011 - Phase 3Taking peopleAcalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- Where
- Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
- Age
- 61 years and over
- People
- 330 worldwide
- Run by
- Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00 - Phase 2Taking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Augsburg, Berlin, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig, Muenster, Munich, Regensburg, Tuebingen
- Age
- 18 years to 70 years
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Augsburg, Chemnitz, Dortmund, Dresden, Duesseldorf, Erfurt, Hannover, Homburg, Jena, Muenster, Munich, Ulm, Wuerzburg
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00 - Phase 3Taking peopleEarly Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
- Where
- Berlin, Essen, Goettingen, Hamburg, Heidelberg, Kiel, Moenchengladbach, Munich, Oldenburg, Regensburg, Rostock, Stuttgart, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 100
- Run by
- Heidelberg University
See details and how to joinNCT05045664 · EU 2023-509278-41-00 - Phase 1/2Taking peopleTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Where
- Heidelberg
- Age
- 3 years and over
- People
- 68
- Run by
- University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00